慢性傷口：市場洞察、流行病學和市場預測（2036 年）

慢性傷口領域的洞察與趨勢

• 由於糖尿病、周邊血管疾病和運動功能下降等與老齡化相關的慢性疾病盛行率不斷上升，慢性傷口的風險顯著增加。缺乏運動、營養不良和吸菸等生活方式因素會進一步抑制傷口癒合過程，導致傷口發生率增加、復原延遲和復發率升高。
• 診斷技術的進步和醫護人員意識提升有望加速慢性傷口的早期發現和準確診斷。預計這一趨勢將提高報告率，並在預測期（2026-2036年）內增加接受治療的患者人數。
• 慢性傷口的主要類型包括糖尿病足潰瘍、靜脈性腿部潰瘍、動脈性潰瘍和壓瘡。雖然每種傷口的病因各不相同，但它們都具有與血流不足和組織損傷相關的通用病理機制。
• 目前的治療方案包括生物製藥（如Becaplermin） 、細胞療法（如DERMAGRAFT和APLIGRAF）以及生長因子（如TRAFERMIN）。此外，還採用了多種輔助治療方法，包括先進的傷口敷料、清創產品、負壓傷口治療、高壓氧氣療法和遠端醫療正日益受到關注。
• 缺乏可靠的生物標記來評估傷口進展和預測癒合過程仍然是一項重大挑戰。這項限制阻礙了及時介入、風險分層和個人化治療方案的實施，最終影響臨床療效。
• 由於缺乏關於慢性傷口的最新、全面的流行病學數據，難以準確評估疾病負擔。這個限制影響了醫療保健規劃、資源分配和有針對性的公共衛生干預措施的製定，最終降低了整體治療效率。
• 包括TTAX01和ELU42等再生醫學產品以及組織衍生產品在內的新型治療方法正在研發中，並有望解決癒合過程中面臨的根本性挑戰。透過持續的研發努力，市場預計將轉向更具針對性的解決方案，這些方案有可能改變疾病的進程。

這份慢性傷口市場報告全面分析了當前的市場格局，包括標準治療方案、臨床實踐和不斷發展的治療流程。該報告還評估了慢性傷口患者的負擔趨勢、收入和市場佔有率趨勢、患者佔有率尖峰時段以及治療方案的採納情況，並對全球各地區的市場規模和成長率預測（歷史數據和2022-2036年預測）進行了詳細評估。透過強調慢性傷口領域尚未滿足的關鍵醫療需求，並分析競爭格局和臨床狀況以識別高價值機遇，本報告清楚地展望了未來的市場成長潛力。

慢性傷口市場的主要促進因素

慢性疾病作為潛在病症的盛行率不斷上升

糖尿病、心血管疾病和肥胖等疾病導致的全球疾病負擔日益加重，是慢性傷口（尤其是糖尿病足潰瘍和靜脈性腿部潰瘍）發生的主要因素。人口老化加劇了這一趨勢，導致需要長期創傷護理照護的患者群體持續成長。

意識的提高和診斷技術的改進

醫護人員和病患意識提升，以及診斷技術的進步和傷口評估方案的標準化，使得早期發現和介入成為可能。這種向及時診斷的轉變正在改善臨床療效，並增加接受治療的患者人數。

創傷護理技術和生物製藥的進展

包括生物工程皮膚替代物、生長因子療法、幹細胞療法和負壓傷口治療在內的先進創傷護理創新技術正在改變治療模式。這些技術透過解決血管生成受損和慢性發炎等潛在的病理學障礙，推動了市場成長。

慢性傷口的理解與治療流程

慢性傷口概述

慢性傷口是指在預期時間內無法癒合的傷口。這類傷口分佈廣泛，常被誤診誤治。如果在篩檢後 4 至 6 週內傷口仍未完全癒合，則被視為慢性傷口或難癒合傷口。靜脈潰瘍（靜脈潰瘍和動脈性潰瘍）、糖尿病足潰瘍 (DFU) 和壓瘡都是常見的慢性傷口。雖然慢性傷口的症狀可能因原因而異，但最常見的識別方法是觀察傷口邊緣隆起、增生或活動受限。傷口周圍會出現炎症，這會阻礙癒合過程。其他常見徵兆和症狀包括出血、腫脹、疼痛或水痘、傷口周圍皮膚顏色變深、患處活動度下降、傷口擴大或加深、發熱、搔癢、乳白色膿液以及觸之發熱或灼熱感。

慢性傷口的診斷

臨床評估傷口的第一步是區分急性傷口和慢性傷口。接下來進行全面的身體檢查，評估傷口的大小、深度、位置以及是否有感染徵兆。此外，檢查周圍皮膚和組織徵兆有發炎、壞死或水腫也至關重要。了解患者的病歷也十分重要，因為糖尿病、周邊血管疾病、免疫抑制以及既往創傷治療癒合併發症等情況都會顯著影響傷口癒合。因此，病歷通常包含傷口的位置、大小、深度、是否有滲液以及組織類型等詳細資訊。根據傷口的位置和外觀，可以根據其根本原因對大多數慢性傷口進行分類，從而製定適當的評估和治療提案。

慢性傷口的治療

對患者和傷口進行全面評估有助於識別需要解決的潛在問題，從而指南後續治療方案。對於糖尿病患者，通常需要控制和改善高血糖、腎功能障礙、營養狀況以及其他可能對傷口癒合產生負面影響的相關合併症。靜脈潰瘍患者常出現血流動力學紊亂，可能需要加強醫療管理。壓瘡患者常因合併症而臥床不起，且有嚴重的營養缺乏，需要矯正這些營養缺乏才能最佳化組織修復。

治療主要著眼於病因。首先，所有慢性傷口都應遵循「TIME」原則進行處理：組織清創（除動脈潰瘍外均需進行）、感染控制、體液平衡和傷口邊緣處理。有效控制慢性傷口感染包括清創以去除壞死組織、細胞碎片和生物膜，以及合理使用抗菌藥物（包括局部消毒劑和全身性抗生素）。

慢性傷口的流行病學

慢性傷口流行病學分析和預測的主要發現

• 根據 DelveInsight 的分析，到 2025 年，七個主要國家確診的慢性傷口病例總數總合將達到約 1,200 萬例。
• 到2025年，美國將出現約710萬例此類病例。其中，壓瘡約佔38%，糖尿病足潰瘍約佔35%，靜脈潰瘍約佔18%，其他類型的慢性傷口約佔9%。
• 在歐盟四國和英國中，德國的慢性傷口病例最多，確診病例近百萬例，其次是法國和英國。預計到2036年，這些數字還將繼續成長，這主要是由於對該疾病的研究和臨床試驗的重視程度不斷提高。
• 在日本，已確診的慢性傷口病例（按類型）構成如下：到 2025 年，壓瘡將佔近 54%，成為最常見的傷口類型，其次是靜脈潰瘍，約佔 23%，糖尿病足潰瘍佔 10%，其他類型佔 10%。

慢性傷口市場展望

表淺傷口的癒合需要多種因素共同作用。此外，傷口敷料和治療方法也取得了顯著進步，以應對從感染到缺氧等可能阻礙創傷治療的各種因素。即使在理想條件下，受損組織的強度也無法完全恢復，一些異常的癒合情況會導致傷口難以癒合。儘管技術取得了長足進步，各種傷口護理也層出不窮，但難癒合傷口仍然是醫生面臨的一大挑戰。為了更好地管理此類傷口，人們開發了多種非手術方法，並引入了許多藥物。

清創術是指移除壞死傷口組織的手術，可採用外科手術、自體溶解、酵素、生物或機械方法進行。目前有多種保濕敷料可用於慢性傷口的治療，但理想的敷料應能保持傷口表面濕潤，同時避免過度潮濕或乾燥。保濕敷料種類繁多，但五大基本類別包括薄膜敷料、泡棉敷料、親水膠體、藻酸鹽敷料和水凝膠敷料。除敷料外，負壓傷口治療（NPWT，也稱為真空輔助封閉療法）也主要用於治療糖尿病足潰瘍和壓瘡等慢性傷口。隨著慢性傷口的進展，需要更先進的技術來改善這種情況。儘管如此，諸如TTAX01等前景廣闊的治療方法的出現，預計將在預測期（2026-2036年）內對市場規模產生積極影響。

• 預計到 2025 年，七大主要國家的慢性傷口市場規模將達到 90 億美元，並預計在預測期（2026-2036 年）內繼續擴大。
• 在歐盟四國和英國中，德國佔最大的市場佔有率，約26%，其次是法國，約21%，英國約20%。預計在預測期（2026-2036年）內，這些數據將會發生變化，這主要得益於持續的研發工作，這些工作有望發現更有效的慢性傷口藥物和治療方法。
• 截至 2025 年，日本慢性傷口市場約佔七大主要國家市場總規模的 6%，但預計到 2036 年，這些數字將會改變。

基於生長因子的療法：靶向生物製藥，例如Becaplermin，可促進細胞增殖、血管生成和肉芽組織形成，從而促進傷口縫合。雖然這些療法代表著生物活性治療的重要一步，但其臨床療效通常僅限於特定類型的傷口，並且需要配合標準輔助療法。

細胞療法和再生醫學：幹細胞療法、富血小板血漿（PRP）療法和生物工程皮膚替代物等方法旨在恢復組織完整性並增強癒合能力。這些療法針對慢性傷口的關鍵問題，包括細胞訊號傳遞受損和細胞外基質功能障礙。然而，在擴大治療規模、成本、臨床結果差異以及長期療效方面仍存在挑戰。

目錄

第1章：主要見解

第2章：引言

第3章：慢性傷口：執行摘要

第4章 主要事件

第5章：流行病學和市場預測的調查方法

第6章 慢性傷口：市場概覽

• 2025 年市佔率（%）及依治療方法分類的詳細情形
• 2036 年市佔率（%）及依治療方法分類的組成

第7章 慢性傷口：疾病背景與概述

• 慢性傷口：病因
• 慢性傷口：徵兆和症狀
• 慢性傷口：發病機制
• 慢性傷口皮膚搔癢的病理生理學
• 慢性傷口：診斷

第8章 慢性傷口：治療與管理

• 傷口管理
• 皮膚和傷口管理

第9章 指導原則

• 診斷指南
  • 慢性傷口臨床實務指引：診斷檢測。

第10章 慢性傷口：流行病學和病人族群

• 前提和基礎
• 慢性傷口：確診患者總數，主要7個國家
• 美國
  • 慢性傷口：美國確診患者總數
  • 慢性傷口：按類型分類的確診患者人數，美國
  • 慢性傷口：美國治療病例總數
• 歐盟4和英國
  • 慢性傷口：歐盟四國和英國確診患者總數
  • 慢性傷口：按類型分類的診斷盛行率，歐盟四國和英國
  • 慢性傷口：歐盟四國和英國的治療病例總數
• 日本
  • 慢性傷口：日本確診患者總數
  • 日本慢性傷口：按類型分類的確診患者人數
  • 慢性傷口：日本治療病例總數

第11章：病患進展

第12章 非處方藥

• 慢性傷口：競爭格局
• Becaplermin（REGRANEX）：林奇再生醫學
  • 產品概述
  • 監管里程碑
  • 其他發展活動
  • 主要臨床試驗概述
  • 分析師意見
• ON-101（BONVADIS）：Oneness Biotech
  • 安全性和有效性

第13章：新興治療藥物

• 慢性傷口：新的競爭格局
• TTAX01：生物組織
  • 產品概述
  • 其他發展活動
  • 臨床開發活動
  • 安全性和有效性
  • 分析師意見

第14章 慢性創傷：七國集團國家分析

• 市場展望
• 市場預測的關鍵假設
  • 成本假設和回扣
  • 價格趨勢
  • 對類似產品的評價
  • 發布年份及療程的普及程度
• 聯合分析
• 慢性傷口：市場規模，主要7個國家
• 市場規模：美國
  • 慢性傷口：市場規模（美國）
  • 美國慢性傷口治療市場規模（按現有和新興療法分類）
• 市場規模：歐盟四國及英國
  • 慢性傷口：市場規模，歐盟四國和英國
  • 歐盟四國和英國慢性傷口市場規模（按現有和新興療法分類）
• 市場規模：日本
  • 日本慢性傷口：市場規模
  • 日本慢性傷口市場規模（按現有和新興治療方法分類）

第15章 慢性傷口：未被滿足的需求

第16章 慢性傷口：SWOT分析

第17章 慢性傷口：關鍵意見領袖（KOL）

第18章 慢性傷口：市場進入與報銷

• 美國
  • 美國醫療保險和醫療補助服務中心（CMS）
• 歐盟4和英國
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國
• 日本
  • MHLW
• 慢性傷口：市場准入與報銷

第19章附錄

第20章：DelveInsight的服務

第21章免責聲明

第22章：關於DelveInsight

Chronic Wounds Insights and Trends

• The increasing prevalence of age-related and chronic conditions such as Diabetes Mellitus, peripheral vascular disease, and immobility is significantly elevating the risk of chronic wounds. Lifestyle factors, including physical inactivity, poor nutrition, and smoking, further impair healing processes, contributing to higher incidence, delayed recovery, and increased recurrence rates.
• Advancements in diagnostic techniques and growing awareness among healthcare professionals are expected to enhance early detection and accurate diagnosis of chronic wounds. This trend is likely to improve reporting rates and expand the treated patient population during the forecast period (2026-2036).
• The major types of chronic wounds include diabetic foot ulcers, venous leg ulcers, arterial ulcers, and pressure ulcers, each with distinct etiologies but overlapping pathological mechanisms related to poor perfusion and tissue damage.
• The current treatment paradigm includes biologics such as Becaplermin, cell-based therapies like DERMAGRAFT and APLIGRAF, and growth factors such as TRAFERMIN. In addition, a wide range of adjunctive approaches, including advanced dressings, wound debridement products, negative pressure wound therapy, hyperbaric oxygen therapy, and bioengineered skin substitutes, are utilized. Despite this diversity, most therapies are supportive and fail to consistently deliver durable, complete healing outcomes. Emerging innovations such as smart wound dressings and telemedicine-based wound monitoring are gaining traction.
• The absence of reliable biomarkers for assessing wound progression and predicting healing trajectories remains a critical gap. This limitation hinders timely intervention, risk stratification, and personalized treatment approaches, ultimately impacting clinical outcomes.
• The scarcity of recent and comprehensive epidemiological data on chronic wounds restricts accurate disease burden estimation. This limitation affects healthcare planning, resource allocation, and the design of targeted public health interventions, thereby reducing overall treatment efficiency.
• Novel therapeutic approaches, including regenerative and tissue-based products such as TTAX01 and ELU42, are under development and hold potential to address underlying healing deficits. Continued R&D efforts are expected to shift the market toward more targeted and potentially disease-modifying solutions.

DelveInsight's 'Chronic Wounds - Market Insights, Epidemiology and Market Forecast - 2036' report delivers an in-depth understanding of the chronic wounds, historical and forecasted epidemiology, as well as the chronic wounds market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

The chronic wounds market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates chronic wounds patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment, and growth rate projections (Historical & Forecast 2022-2036) across global regions. The report highlights key unmet medical needs in chronic wounds and maps the competitive and clinical landscape to uncover high-value opportunities, providing a clear outlook on future market growth potential.

Key Factors Driving the Chronic Wounds Market

Rising prevalence of underlying chronic conditions

The increasing global burden of diseases such as diabetes mellitus, cardiovascular disorders, and obesity is significantly contributing to the incidence of chronic wounds, particularly diabetic foot ulcers and venous leg ulcers. Aging populations further exacerbate this trend, leading to a sustained and expanding patient pool requiring long-term wound care management.

Growing awareness and improved diagnosis

Enhanced awareness among healthcare professionals and patients, coupled with improved diagnostic techniques and standardized wound assessment protocols, is enabling earlier identification and intervention. This shift toward timely diagnosis is improving clinical outcomes and increasing the number of patients entering the treatment pathway.

Advancements in wound care technologies and biologics

Innovations in advanced wound care, including bioengineered skin substitutes, growth factor therapies, stem cell-based approaches, and negative pressure wound therapy, are transforming treatment paradigms. These technologies address underlying pathophysiological barriers such as impaired angiogenesis and chronic inflammation, thereby driving market growth.

Chronic Wounds Understanding and Treatment Algorithm

Chronic Wounds Overview

Chronic wounds are defined as wounds with an inability to heal within an anticipated time frame. They are widespread and frequently mistreated. A wound is considered chronic or non-healing when it has not fully healed even after four to six weeks of screening. Venous ulcers (Vein ulcers, arterial ulcers), diabetic foot ulcers (DFU), and pressure ulcers are examples of common chronic wound types. While different etiologies of chronic wounds are associated with slightly different symptoms, the most common way to recognize a chronic wound is by its elevated, hyperproliferative, yet immobile wound edge. There will be inflammation in the vicinity of the wound, which could harm the healing process. Other common signs and symptom checklists include bleeding, swelling, pain or blistering, darkened skin around the wound, difficulty moving the injured area, enlarged or deepened injury, fever, itching, milky pus, and warmth or heat when touched.

Chronic Wounds Diagnosis

The initial step in evaluating a wound clinically involves distinguishing between acute and chronic wounds. This is followed by a thorough physical examination, which includes assessing the wound's size, depth, location, and any indications of infection. Additionally, inspecting the surrounding skin and tissues for signs like inflammation, necrosis, or edema is crucial. Understanding the patient's medical history is also paramount, as conditions such as diabetes, peripheral vascular disease, immunosuppression, and prior wound healing complications can significantly impact healing. Consequently, documentation typically includes details such as the wound's location, size, depth, presence of drainage, and tissue type. By considering the wound's location and appearance, most chronic wounds can be categorized by their underlying cause, facilitating appropriate assessment and treatment recommendations.

Chronic Wounds Treatment

A thorough assessment of the patient and the wound will guide subsequent treatment by elucidating underlying areas of concern that need to be addressed. Diabetic patients frequently need improved control of their hyperglycemia, renal insufficiency, nutrition, and other associated medical comorbidities that may adversely affect the healing of their wound(s). Patients with venous leg ulcers might often have hemodynamic perturbations requiring improved medical management. Pressure ulcer patients, often bedridden from intercurrent illness, will have significant nutritional deficits that need to be corrected to optimize tissue repair.

Treatment primarily focuses on treating the cause. First, all chronic wounds should be managed according to the principle of TIME: tissue debridement (in all cases except arterial ulcers), infection control, fluid balance, and wound margins. Effective management of infection in chronic wounds includes removal of necrotic tissue, cellular debris, and biofilm by debridement, and appropriate use of antimicrobial agents (including topical antiseptics and systemic antibiotics).

Chronic Wounds Unmet Needs

The section "unmet needs of chronic wounds" outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress.

1. Lack of effective, durable healing therapies

2. Delayed diagnosis and poor risk stratification

3. High recurrence rates

4. Limited access to advanced therapies

5. Inadequate pain and quality-of-life management, and others.....

Comprehensive unmet needs insights in chronic wounds and their strategic implications are provided in the full report.

Chronic Wounds Epidemiology

Key Findings from Chronic Wounds Epidemiological Analysis and Forecast

• As per DelveInsight analysis, in 2025, the total diagnosed prevalent cases of chronic wounds in the 7MM are estimated to be approximately 12 million cases.
• In 2025, the US accounted for approximately 7.1 million cases. Among these, pressure ulcers accounted for approximately 38%, diabetic foot ulcers for 35%, venous ulcers for 18%, and other types of chronic wounds for the remaining 9%.
• Among the EU4 and the UK, Germany accounted for the highest cases, i.e., nearly 1 million diagnosed prevalent cases of chronic wounds, followed by France and the UK. These cases are expected to rise by 2036 primarily due to the heightened focus on research and clinical trials for the disease.
• Among type-specific diagnosed prevalent cases of chronic wounds in Japan, pressure ulcers had the highest contribution of cases in 2025, with nearly 54% cases, followed by around 23%, 10%, and 10% cases for venous ulcers, diabetic foot ulcers, and others, respectively.

Chronic Wounds Drug Chapters & Competitive Analysis

The chronic wounds drug chapter provides a detailed, market-focused review of approved therapies and the emerging pipeline across Phase I-III clinical trials. It covers the mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, and strategic partnerships for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the chronic wounds treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the chronic wounds therapeutics market.

Approved Therapies for Chronic Wounds

Becaplermin (REGRANEX): Lynch Regenerative Medicine

Becaplermin is indicated for treating lower extremity diabetic neuropathic ulcers that extend into the subcutaneous tissue or beyond and have an adequate blood supply when used as an adjunct to, and not a substitute for, good ulcer care practices, including initial sharp debridement, pressure relief, and infection control. REGRANEX Gel contains becaplermin, a recombinant human platelet-derived growth factor (rhPDGF-BB) for topical administration. Becaplermin is produced by recombinant DNA technology by inserting the gene for the B chain of platelet-derived growth factor (PDGF) into the yeast Saccharomyces cerevisiae.

In March 2025, Lynch Regenerative Medicine announced that it had acquired exclusive rights to REGRANEX gel and recombinant purified platelet-derived growth factor (PDGF) from Smith & Nephew, for use in skin rejuvenation and regeneration, as well as other soft tissue wound healing and tissue regeneration applications. PDGF is the first and only pure recombinant growth factor to have received approval from the US FDA for the treatment of wounds in the lower extremities of diabetic patients.

ON-101 (BONVADIS): Oneness Biotech

ON-101 is a new botanical drug ointment that possesses the function of diabetic wound healing and high safety. The active pharmaceutical ingredient (API) of ON101 is composed of extracts from two commonly used traditional Chinese herbal medicines, Plectranthus amboinicus and Centella asiatica. It is a first-in-class drug targeting the subsets of macrophages to promote the healing of chronic wounds. It has been demonstrated with superior efficacy to the standard care dressing in a Phase III MRCT completed in the US, Taiwan, and China.

• In March 2026, Oneness received an EU Notified Body (ECM) issued EU Quality Management System Certificate (EU market approval) that grants marketing authorization across all 27 EU member states for BONVADIS, used for acute and chronic wounds and scar management.
• In June 2025, Oneness Biotech announced a major milestone in its global commercialization, with the US FDA granting market approval for BONVADIS cream for full-thickness chronic wound indications. The approved indications include full-thickness and partial-thickness wounds, post-surgical wounds, first- and superficial second-degree burns, as well as chronic wounds such as diabetic foot ulcers, venous ulcers, and pressure sores, effectively covering both acute and chronic wound indications in the US market.

Chronic Wounds Pipeline Analysis

TTAX01: Biotissue

TTAX01 is being developed by Biotissue to manage diabetic foot ulcer (DFU) and non-healing wounds. It is a cryopreserved human umbilical cord product derived from donated human placental tissue following healthy, live, caesarean section, full-term births after determining donor eligibility and placenta suitability. The company's proprietary technology, the CRYOTEK process, which devitalizes the living cells but retains the natural structural and biological characteristics relevant to this tissue, is being used. TTAX01 is aseptically processed in compliance with current Good Tissue Practices (cGTP).

The drug candidate is being investigated in two planned multicenter randomized controlled Phase III clinical trials conducted at 20 investigational sites across the US, with 220 patients in each trial. These trials, titled AMBULATE DFU and AMBULATE DFU II, are expected to evaluate the benefits and risks of using TTAX01 to achieve complete wound closure of complex non-healing DFUs with high-risk factors of ulcer depth indicating exposed bone, tendon, muscle, and/or joint capsule, and clinical suspicion of osteomyelitis.

Chronic Wounds Key Players, Market Leaders, and Emerging Companies

• Biotissue
• Smith & Nephew
• Lynch Regenerative Medicine
• Kaken Pharmaceutical
• Oneness Biotech, and others

Chronic Wounds Drug Updates

• In March 2026, Oneness received an EU Notified Body (ECM) issued EU Quality Management System Certificate (EU market approval) that grants marketing authorization across all 27 EU member states for BONVADIS, used for acute and chronic wounds and scar management.
• In June 2025, Oneness Biotech announced a major milestone in its global commercialization, with the US FDA granting market approval for BONVADIS cream for full-thickness chronic wound indications. The approved indications include full-thickness and partial-thickness wounds, post-surgical wounds, first- and superficial second-degree burns, as well as chronic wounds such as diabetic foot ulcers, venous ulcers, and pressure sores, effectively covering both acute and chronic wound indications in the US market.
• In March 2025, Lynch Regenerative Medicine announced that it had acquired exclusive rights to REGRANEX gel and recombinant purified PDGF from Smith & Nephew, for use in skin rejuvenation and regeneration, as well as other soft tissue wound healing and tissue regeneration applications. PDGF is the first and only pure recombinant growth factor to have received approval from the US FDA for the treatment of wounds in the lower extremities of diabetic patients.

Chronic Wounds Market Outlook

Numerous elements must cooperate for a superficial wound to heal; moreover, wound dressings and treatments have advanced significantly to address potential obstacles to wound healing, from infection to hypoxia. Even under ideal conditions, the strength of the injured tissue never restores, and several aberrant healing states can lead to persistent non-healing wounds. Despite significant advances in technological innovation and the advent of various wound treatments, non-healing wounds continue to challenge physicians. Various nonsurgical approaches have been developed, and many drugs have been introduced to assist in managing such wounds.

Debridement is the removal of nonviable wound tissue, and it can be performed using surgical, autolytic, enzymatic, biological, or mechanical methods. Although several moisture-retentive dressings are available to manage chronic wounds, the best dressing is the one that keeps the wound moist but not too wet or dry. While there are multiple types of moisture-retentive dressings, the five basic categories include films, foams, hydrocolloids, alginates, and hydrogels. In addition to dressings, NPWT (also known as vacuum-assisted closure) has been used primarily in chronic wound management for diabetic foot ulcers and pressure ulcers. With the advancement of chronic wounds, there is a need for a more advanced technique to cure this situation. Nonetheless, the anticipated release of promising treatments like TTAX01 and others is anticipated to positively influence the market size throughout the forecast period (2026-2036).

• The market size of chronic wounds in the 7MM is USD 9,000 million in 2025, which is expected to rise in the forecast period (2026-2036).
• Among the EU4 and the UK, Germany holds the highest market size of around 26%, followed by France and the UK with approximately 21% and 20% respectively. These numbers are expected to change during the forecast period (2026-2036), driven by the ongoing research and development efforts that may lead to the discovery of more effective medications and therapies for treating chronic wounds.
• The chronic wound market size in Japan accounted for nearly 6% of the total 7MM market size in 2025; these numbers are expected to change by 2036.

Drug Class/Insights into Leading Emerging and Marketed Therapies in Chronic Wounds (2026-2036 Forecast)

The chronic wounds therapeutic landscape remains largely supportive and symptom-driven; however, recent advances in regenerative medicine and biologics are initiating a shift toward mechanism-based approaches that target the underlying drivers of impaired healing, such as chronic inflammation, poor angiogenesis, and tissue hypoxia.

Growth factor-based therapies: Targeted biologics such as Becaplermin promote cellular proliferation, angiogenesis, and granulation tissue formation, supporting wound closure. While these therapies represent an important step toward biologically active treatment, their clinical impact is often limited to specific wound types and requires adjunctive standard care.

Cell and regenerative therapies: Approaches including stem cell-based treatments, platelet-rich plasma (PRP), and bioengineered skin substitutes aim to restore tissue integrity and enhance healing capacity. These therapies address key deficits in chronic wounds, such as impaired cellular signaling and extracellular matrix dysfunction. However, challenges related to scalability, cost, variability in clinical outcomes, and long-term durability persist.

Chronic Wounds Drug Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during the forecast period (2026-2036). The analysis covers the chronic wounds market's uptake by drugs, patient uptake by therapy, and sales of each drug.

Drug uptake in chronic wounds is currently highest for Oneness Biotech's ON101, a new botanical drug ointment that possesses the function of diabetic wound healing and high safety to reduce wound inflammation, increase epithelialization of the epidermal tissues, promote collagen production, and decrease granulation tissue development in the wound.

Market Access and Reimbursement of Chronic Wounds

• US

Reimbursement is a crucial factor that affects the drug's access to the market. Often, the decision to reimburse comes down to the price of the drug relative to the benefit it produces in treated patients. To reduce the healthcare burden of these high-cost therapies, many payment models are being considered by payers and other industry insiders.

Further details are provided in the final report....

Chronic Wounds Therapies Price Scenario & Trends

Pricing and analogue assessment of chronic wound therapies highlights evolving price dynamics structures. This section summarizes the cost of approved treatments, the closest and most appropriate analogue selection for emerging therapies, and the understanding of how pricing influences market access, adherence, and long-term uptake.

• Pricing of Chronic Wound-Approved Drugs

In the current treatment paradigm, advanced therapies for chronic wounds, including skin substitutes and growth factors, cost approximately USD 4,200, with many patients requiring multiple applications to achieve healing.

Further details are provided in the final report....

Industry Experts and Physician Views for Chronic Wounds

To keep up with chronic wounds market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on the chronic wounds emerging therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns in chronic wounds, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight's analysts connected with 10+ KOLs to gather insights; however, interviews were conducted with 6+ KOLs in the 7MM. Centers such as the University of North Carolina at Chapel Hill, the Berlin Institute of Health at Charite, and the University of Nottingham, etc. were contacted. Their opinion helps understand and validate current and emerging chronic wounds therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in chronic wounds.

Qualitative Analysis: SWOT and Conjoint Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and conjoint analysis.

In the SWOT analysis of Chronic Wounds, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team of analysts analyzes promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial's primary and secondary outcome measures are evaluated, whereas the therapies' safety is evaluated, wherein the acceptability, tolerability, and adverse events are mainly observed. In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Scope of the Report:

• The report covers a segment of key events, an executive summary, a descriptive overview of chronic wounds, explaining their causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the chronic wounds market, historical and forecasted market size, and market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM chronic wounds market.

Report Insights

• Chronic Wounds Patient Population Forecast
• Chronic Wounds Therapeutics Market Size
• Chronic Wounds Pipeline Analysis
• Chronic Wounds Market Size and Trends
• Chronic Wounds Market Opportunity (Current and forecasted)

Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• Artificial Intelligence (AI)-enabled Market Research Report
• 11-year forecast
• Chronic Wounds Market Outlook (North America, Europe, Asia-Pacific)
• Patient Burden Trends (by geography)
• Chronic Wounds Treatment Addressable Market (TAM)
• Chronic Wounds Competitive Landscape
• Chronic Wounds Major Companies Insights
• Chronic Wounds Price Trends and Analogue Assessment
• Chronic Wounds Therapies Drug Adoption/Uptake
• Chronic Wounds Therapies Peak Patient Share Analysis

Report Assessment

• Chronic Wounds Current Treatment Practices
• Chronic Wounds Unmet Needs
• Chronic Wounds Clinical Development Analysis
• Chronic Wounds Emerging Drugs Product Profiles
• Chronic Wounds Market Attractiveness
• Chronic Wounds Qualitative Analysis (SWOT and Conjoint Analysis)

FAQs:

Market Insights

• What was the chronic wounds market size, the market size by therapies, the market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of chronic wounds?
• What are the disease risks, burdens, and unmet needs of chronic wounds? What will be the growth opportunities across the 7MM concerning the patient population with chronic wounds?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of chronic wounds? What are the current guidelines for treating Chronic Wounds in the US, Europe, and Japan?

Reasons to Buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the chronic wounds market.
• Bottom up forecasting builds from the affected population to product forecasts, delivering a robust, data driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• To understand KOLs' perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights into the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI) enabled report summarize and simplify complex datasets within the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary of Chronic Wounds

4. Key Events

• 4.1. Upcoming Key Catalysts
• 4.2. Key Conferences and Meetings
• 4.3. Key Transactions and Collaborations
• 4.4. News Flow

5. Epidemiology and Market Forecast Methodology

6. Chronic Wounds Market Overview at a Glance

• 6.1. Market Share (%) Distribution by Therapies in 2025
• 6.2. Market Share (%) Distribution by Therapies in 2036

7. Disease Background and Overview of Chronic Wounds

• 7.1. Introduction
• 7.2. Causes of Chronic Wounds
• 7.3. Signs and Symptoms of Chronic Wounds
• 7.4. Pathogenesis of Chronic Wounds
• 7.5. Pathophysiology of Itch in Chronic Wound Skin
• 7.6. Diagnosis of Chronic Wounds

8. Treatment and Management of Chronic Wounds

• 8.1. Management of Wounds
• 8.2. Skin and Wound Management

9. Guidelines

• 9.1. Diagnostic Guidelines
  • 9.1.1. Clinical Practice Guidelines for Chronic Wounds: Laboratory Diagnosis

10. Epidemiology and Patient Population of Chronic Wounds

• 10.1. Key Findings
• 10.2. Assumption and Rationale
• 10.3. Total Diagnosed Prevalent Cases of Chronic Wounds in the 7MM
• 10.4. The United States
  • 10.4.1. Total Diagnosed Prevalent Cases of Chronic Wounds in the United States
  • 10.4.2. Type-specific Diagnosed Prevalent Cases of Chronic Wounds in the United States
  • 10.4.3. Total Treated Cases of Chronic Wounds in the United States
• 10.5. EU4 and the UK
  • 10.5.1. Total Diagnosed Prevalent Cases of Chronic Wounds in EU4 and the UK
  • 10.5.2. Type-specific Diagnosed Prevalent Cases of Chronic Wounds in EU4 and the UK
  • 10.5.3. Total Treated Cases of Chronic Wounds in EU4 and the UK
• 10.6. Japan
  • 10.6.1. Total Diagnosed Prevalent Cases of Chronic Wounds in Japan
  • 10.6.2. Type-specific Diagnosed Prevalent Cases of Chronic Wounds in Japan
  • 10.6.3. Total Treated Cases of Chronic Wounds in Japan

11. Patient Journey

12. Marketed Drugs

• 12.1. Marketed Competitive Landscape of Chronic Wounds
• 12.2. Becaplermin (REGRANEX): Lynch Regenerative Medicine
  • 12.2.1. Product Description
  • 12.2.2. Regulatory Milestones
  • 12.2.3. Other Developmental Activities
  • 12.2.4. Summary of Pivotal Trials
    • 12.2.4.1. Safety and Efficacy
  • 12.2.5. Analyst's View
• 12.3. ON-101 (BONVADIS): Oneness Biotech
  • 12.3.1. Product Description
  • 12.3.2. Regulatory Milestones
  • 12.3.3. Other Developmental Activities
  • 12.3.4. Summary of Pivotal Trials
  • 12.3.5. Safety and Efficacy
  • 12.3.6. Analyst's View

13. Emerging Drugs

• 13.1. Emerging Competitive Landscape of Chronic Wounds
• 13.2. TTAX01: Biotissue
  • 13.2.1. Product Description
  • 13.2.2. Other Developmental Activities
  • 13.2.3. Clinical Developmental Activities
    • 13.2.3.1. Clinical Trial Information
  • 13.2.4. Safety and Efficacy
  • 13.2.5. Analyst's View

14. Chronic Wounds: 7MM Analysis

• 14.1. Key Findings
• 14.2. Market Outlook
• 14.3. Key Market Forecast Assumptions
  • 14.3.1. Cost Assumptions and Rebates
  • 14.3.2. Pricing Trends
  • 14.3.3. Analogue Assessment
  • 14.3.4. Launch Year and Therapy Uptakes
• 14.4. Conjoint Analysis
• 14.5. Total Market Size of Chronic Wounds in the 7MM
• 14.6. United States Market Size
  • 14.6.1. Total Market Size of Chronic Wounds in the United States
  • 14.6.2. Market Size of Chronic Wounds by Current and Emerging Therapies in the United States
• 14.7. EU4 and the UK Market Size
  • 14.7.1. Total Market Size of Chronic Wounds in EU4 and the UK
  • 14.7.2. Market Size of Chronic Wounds by Current and Emerging Therapies in EU4 and the UK
• 14.8. Japan Market Size
  • 14.8.1. Total Market Size of Chronic Wounds in Japan
  • 14.8.2. Market Size of Chronic Wounds by Current and Emerging Therapies in Japan

15. Unmet Needs of Chronic Wounds

16. SWOT Analysis of Chronic Wounds

17. KOL Views of Chronic Wounds

18. Market Access and Reimbursement of Chronic Wounds

• 18.1. United States
  • 18.1.1. Centre for Medicare & Medicaid Services (CMS)
• 18.2. EU4 and the UK
  • 18.2.1. Germany
  • 18.2.2. France
  • 18.2.3. Italy
  • 18.2.4. Spain
  • 18.2.5. United Kingdom
• 18.3. Japan
  • 18.3.1. MHLW
• 18.4. Chronic Wounds: Market Access and Reimbursement

19. Appendix

• 19.1. Bibliography
• 19.2. Report Methodology

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight

List of Tables

• Table 1 Summary of Chronic Wound Market and Epidemiology (2022-2036)
• Table 2 Key Events
• Table 3 Systemic and Local Factors Contributing to Chronic Wounds
• Table 4 PUs Grading System, NPUAP, EPUAP, and PPPIA
• Table 5 Types of Chronic Wounds and Their Pathology
• Table 6 Extended Differential Diagnosis for Chronic Wounds
• Table 7 Clinical Practice Guideline for the Diagnosis of DFIs
• Table 8 Guidelines on the diagnosis of foot infections in persons With Diabetes
• Table 9 Guidelines for the Diagnosis of Pus: JDA
• Table 10 TIME Principles of Wound Bed Preparation
• Table 11 Types of Chronic Wounds and their Specific Therapy
• Table 12 Recommendations on the Use of Antimicrobial Dressings in Wounds
• Table 13 Wound Care Technologies
• Table 14 Clinical Practice Guideline for the Diagnosis and Treatment of DFIs
• Table 15 Guidelines on the Diagnosis and Management of Foot Infections in Persons With Diabetes
• Table 16 Guidelines for Treating Pus: JDA
• Table 17 Total Diagnosed Prevalent Cases of Chronic Wounds in the 7MM, in Thousands (2022-2036)
• Table 18 Total Diagnosed Prevalent Cases of Chronic Wounds in the US, in Thousands (2022-2036)
• Table 19 Type-specific Diagnosed Prevalent Cases of Chronic Wounds in the US, in Thousands (2022-2036)
• Table 20 Total Diagnosed Prevalent Cases of Chronic Wounds in EU4 and the UK, in Thousands (2022-2036)
• Table 21 Type-specific Diagnosed Prevalent Cases of Chronic Wounds in EU4 and the UK, in Thousands (2022-2036)
• Table 22 Total Diagnosed Prevalent Cases of Chronic Wounds in Germany, in Thousands (2022-2036)
• Table 23 Type-specific Diagnosed Prevalent Cases of Chronic Wounds in Germany, in Thousands (2022-2036)
• Table 24 Total Diagnosed Prevalent Cases of Chronic Wounds in France, in Thousands (2022-2036)
• Table 25 Type-specific Diagnosed Prevalent Cases of Chronic Wounds in France, in Thousands (2022-2036)
• Table 26 Total Diagnosed Prevalent Cases of Chronic Wounds in Italy, in Thousands (2022-2036)
• Table 27 Type-specific Diagnosed Prevalent Cases of Chronic Wounds in Italy, in Thousands (2022-2036)
• Table 28 Total Diagnosed Prevalent Cases of Chronic Wounds in Spain, in Thousands (2022-2036)
• Table 29 Type-specific Diagnosed Prevalent Cases of Chronic Wounds in Spain, in Thousands (2022-2036)
• Table 30 Total Diagnosed Prevalent Cases of Chronic Wounds in the UK, in Thousands (2022-2036)
• Table 31 Type-specific Diagnosed Prevalent Cases of Chronic Wounds in the UK, in Thousands (2022-2036)
• Table 32 Total Diagnosed Prevalent Cases of Chronic Wounds in Japan, in Thousands (2022-2036)
• Table 33 Type-specific Diagnosed Prevalent Cases of Chronic Wounds in Japan, in Thousands (2022-2036)
• Table 34 Key Cross of Marketed Drugs
• Table 35 REGRANEX (becaplermin) Clinical Trial Description, 2024
• Table 36 FIBLAST (trafermin) Clinical Trial Description, 2024
• Table 37 Key Cross of Emerging Drugs
• Table 38 ON101, Clinical Trial Description, 2024
• Table 39 TTAX01, Clinical Trial Description, 2024
• Table 40 Key Market Forecast Assumptions for ON101
• Table 41 Key Market Forecast Assumptions for TTAX01
• Table 42 Market Size of Chronic Wounds in the 7MM in USD Million (2022-2036)
• Table 43 Market Size of Chronic Wounds by Therapies in the 7MM, in USD Million (2022-2036)
• Table 44 Market Size of Chronic Wounds in the US, in USD Million (2022-2036)
• Table 45 Market Size of Chronic Wounds by Therapies in the US, in USD Million (2022-2036)
• Table 46 Market Size of Chronic Wounds in Germany, in USD Million (2022-2036)
• Table 47 Market Size of Chronic Wounds by Therapies in Germany, in USD Million (2022-2036)
• Table 48 Market Size of Chronic Wounds in France, in USD Million (2022-2036)
• Table 49 Market Size of Chronic Wounds by Therapies in France, in USD Million (2022-2036)
• Table 50 Market Size of Chronic Wounds in Italy, in USD Million (2022-2036)
• Table 51 Market Size of Chronic Wounds by Therapies in Italy, in USD Million (2022-2036)
• Table 52 Market Size of Chronic Wounds in Spain, USD Million (2022-2036)
• Table 53 Market Size of Chronic Wounds by Therapies in Spain, in USD Million (2022-2036)
• Table 54 Market Size of Chronic Wounds in the UK, USD Million (2022-2036)
• Table 55 Market Size of Chronic Wounds by Therapies in the UK, in USD Million (2022-2036)
• Table 56 Market Size of Chronic Wounds in Japan, in USD Million (2022-2036)
• Table 57 Market Size of Chronic Wounds by Therapies in Japan, in USD Million (2022-2036)

List of Figures

• Figure 1 Chronic Non-healing wounds
• Figure 2 Flow Diagram of Chronic Wound Management
• Figure 3 Types of Chronic Wounds
• Figure 4 Arterial Insufficiency Ulcer Located at Weight Bearing Surface.
• Figure 5 Diabetic Foot Ulcer (DFU) at the First Metatarsal Head of the Foot
• Figure 6 Stages of PUs
• Figure 7 VUs with Granulated Wound Bed and Surrounding Dry, Scaly, Eczematous, and Hyper-pigmented Skin
• Figure 8 Molecular and Cellular Deficiencies in Chronic Wounds (red circles) and Factors Required to Overcome Them (green rectangles)
• Figure 9 Pathophysiology of Chronic Wounds
• Figure 10 The Role of Inflammation in the Pathophysiology of Common Chronic Wounds
• Figure 11 Diagnosing Chronic Wounds: The ABCDE Rule
• Figure 12 Diagnostic Algorithm to Determine Chronic Wound
• Figure 13 Simplified Algorithm for DFU Treatment
• Figure 14 Simplified Algorithm for VLU Treatment. ABI, Ankle-brachial indices
• Figure 15 Algorithm for Management of PU
• Figure 16 Total Diagnosed Prevalent Cases of Chronic Wounds in the 7MM (2022-2036)
• Figure 17 Total Diagnosed Prevalent Cases of Chronic Wounds in the US (2022-2036)
• Figure 18 Type-specific Diagnosed Prevalent Cases of Chronic Wounds in the US(2022-2036)
• Figure 19 Total Diagnosed Prevalent Cases of Chronic Wounds in Germany (2022-2036)
• Figure 20 Type-specific Diagnosed Prevalent Cases of Chronic Wounds in Germany (2022-2036)
• Figure 21 Total Diagnosed Prevalent Cases of Chronic Wounds in France (2022-2036)
• Figure 22 Type-specific Diagnosed Prevalent Cases of Chronic Wounds in France (2022-2036)
• Figure 23 Total Diagnosed Prevalent Cases of Chronic Wounds in Italy (2022-2036)
• Figure 24 Type-specific Diagnosed Prevalent Cases of Chronic Wounds in Italy (2022-2036)
• Figure 25 Total Diagnosed Prevalent Cases of Chronic Wounds in Spain (2022-2036)
• Figure 26 Type-specific Diagnosed Prevalent Cases of Chronic Wounds in Spain (2022-2036)
• Figure 27 Total Diagnosed Prevalent Cases of Chronic Wounds in the UK (2022-2036)
• Figure 28 Type-specific Diagnosed Prevalent Cases of Chronic Wounds in the UK (2022-2036)
• Figure 29 Total Diagnosed Prevalent Cases of Chronic Wounds in Japan (2022-2036)
• Figure 30 Type-specific Diagnosed Prevalent Cases of Chronic Wounds in Japan (2022-2036)
• Figure 31 Patient Journey
• Figure 32 Market Size of Chronic Wounds in the 7MM, in USD Million (2022-2036)
• Figure 33 Market Size of Chronic Wounds by Therapies in the 7MM, in USD Million (2022-2036)
• Figure 34 Market Size of Chronic Wounds in the US, in USD Million (2022-2036)
• Figure 35 Market Size of Chronic Wounds by Therapies in the US, in USD Million (2022-2036)
• Figure 36 Market Size of Chronic Wounds in Germany, in USD Million (2022-2036)
• Figure 37 Market Size of Chronic Wounds by Therapies in Germany, in USD Million (2022-2036)
• Figure 38 Market Size of Chronic Wounds in France, in USD Million (2022-2036)
• Figure 39 Market Size of Chronic Wounds by Therapies in France, in USD Million (2022-2036)
• Figure 40 Market Size of Chronic Wounds in Italy, in USD Million (2022-2036)
• Figure 41 Market Size of Chronic Wounds by Therapies in Italy, in USD Million (2022-2036)
• Figure 42 Market Size of Chronic Wounds in Spain, USD Million (2022-2036)
• Figure 43 Market Size of Chronic Wounds by Therapies in Spain, in USD Million (2022-2036)
• Figure 44 Market Size of Chronic Wounds in the UK, USD Million (2022-2036)
• Figure 45 Market Size of Chronic Wounds by Therapies in the UK, in USD Million (2022-2036)
• Figure 46 Market Size of Chronic Wounds in Japan, USD Million (2022-2036)
• Figure 47 Market Size of Chronic Wounds by Therapies in Japan, in USD Million (2022-2036)
• Figure 48 SWOT
• Figure 49 Unmet Needs